JERSEY CITY, N.J., March 3, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO ® (CT-P41, denosumab-bmwo) and OSENVELT ® (CT-P41, ...
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] STOBOCLO and OSENVELT, among the ...
Credit: Celltrion. The FDA originally approved Stoboclo and Osenvelt as biosimilars in March 2025. The interchangeability designation allows Stoboclo and Osenvelt to be substituted at the pharmacy for ...
"The approval of STOBOCLO and OSENVELT is another step forward in our efforts to deliver cost-effective and high-quality treatments that address critical unmet needs in osteoporosis-related fracture ...
JERSEY CITY, N.J., July 7, 2025 /PRNewswire/ -- Celltrion USA today announced that STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo), biosimilars referencing PROLIA ® (denosumab) and XGEVA ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results